阿托伐他汀对老年冠心病患者血小板α颗粒膜蛋白GMP-140的影响

目的探讨阿托伐他汀对老年冠心病患者血小板α颗粒膜蛋白（GMP-140）的影响。方法80例老年冠心病患者服用阿托伐他汀8周。测定冠心病患者和正常对照者的GMP-140含量并比较冠心病患者服用阿托伐他汀前后总胆固醇、甘油三脂、低密度脂蛋白、血小板α颗粒膜蛋白（GMP-140）的变化。结果发现冠心病患者治疗后总胆固醇、低密度脂蛋白、GMP-140浓度均明显降低，高密度脂蛋白浓度增高。结论阿托伐他汀治疗老年冠心病患者能有效地降低胆固醇。抑制血小板活性。

Effects of Atoravastain on the Plasma Alphagranule Membrane in Old Patients with Coronary Heart Disease

Objective To study the effect of Atoravastain on the plasma alphagranule membrane protein-140 in old patients with coronary heart disease. Methods 80 cases with CHD were treated with Atoravastain for 8 weeks. The plasma GMP-140 levels of the treated patients were compared with healthy control group. The levels of Tgs, LDL and GMP-140 in the patients with cornaty heart disease were measured before and after taking Atoravastain. Results The levels of Tgs, LDL and GMP-140 were significantly lower after treatment. Levels of HDL was significantly higher. Conclusion Atoravastain can treat old patients with coronary heart disease to lower the Tgs level, control the platelet＇s activation, improve endedermis＇s function, and decrease cardiovascular disease. So Ateravastain can reduce the incidence of coronary heart disease,